Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
NCT07885605
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Thyroid Eye Disease (TED)
- Graves' Disease
- Eye Diseases, Hereditary
- Eye Diseases
- Exophthalmos
- Orbital Diseases
- Goiter
- Thyroid Diseases
- Endocrine System Diseases
- Hyperthyroidism
- Autoimmune Diseases
- Immune System Diseases
- Graves Ophthalmopathy
- Proptosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Ethyreal Bio, Inc.
- Last updated on ClinicalTrials.gov
- October 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- Site 105 · Orland Park, IL
North Carolina · 1
- Site 113 · Wilmington, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.